Oruka Therapeutics

We’re excited to announce that the first participants have been dosed in a Phase 1 trial of ORKA-001, our novel, half-life extended monoclonal antibody targeting IL-23p19. Our CMO, Joana Goncalves, shares more about this significant milestone below. Read the full press release here: https://lnkd.in/gWnr2zdS.

We're thrilled to attend the Jefferies London Healthcare Conference this week, where our CEO, Lawrence Klein, will speak about our progress in developing novel biologics for psoriasis and other related diseases. Register for the webcast of our presentation on November 20 here: https://lnkd.in/e5wH7ted.

October 29 is #WorldPsoriasisDay. This year’s theme of “Family” highlights the impact of psoriatic disease on over 100 million people worldwide as well as their loved ones. Psoriasis presents unique challenges not only for those affected but also for their families. At Oruka, we’re dedicated to developing new treatments that aim to ease this burden by offering those living with psoriasis the greatest possible freedom from disease.

We recently celebrated our public listing at the Nasdaq MarketSite in Times Square! We’re proud to mark this achievement along our path to develop novel biologics for plaque psoriasis and related conditions. Photography courtesy of Nasdaq, Inc.

We’re excited to present new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, at the EADV Congress in Amsterdam. The data show that ORKA-001 has a three-fold longer half-life in non-human primates than risankizumab, while binding to a similar epitope with similar affinity. These findings give us additional confidence that ORKA-001 can achieve our base-case expectation of dosing once every six months and further reason to believe we could reach once-yearly dosing with the potential for higher efficacy, all with the goal of offering people with psoriasis the most possible freedom from their disease.

We’re excited to begin trading on Nasdaq as “ORKA” today following the close of our merger. This transaction and concurrent $275 million financing propel us towards our goal of offering the greatest possible freedom from disease to patients with psoriasis and other associated diseases.